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Prognostic Markers in Acute Babesia canis Infections
R.M. Eichenberger, B. Riond, B. Willi, R. Hofmann-Lehmann, and P. Deplazes
Background: Canine babesiosis, caused by Babesia canis, is a prevalent and clinically relevant disease in Europe. Severe
acute babesiosis is characterized by a high mortality but prognosis is not always correlated with clinical signs nor with the
level of parasitemia.
Objective: This study evaluated prognostic markers associated with poor outcomes in acute Babesia canis infections.
Animals and Methods: We compared the results of routine laboratory proﬁles, hand-held lactate and glucose analyzer,
and the acute phase response in 2 groups of naturally infected dogs (7 survivors and 8 nonsurvivors). Samples were collected
at the time of ﬁrst admission and before any treatment. Subsequently, the course of prognostic markers was followed in 3
dogs experimentally inoculated with B. canis.
Results: Nonsurvivors showed signiﬁcantly higher concentrations of lactate, triglycerides and phosphate and lower hemat-
ocrit, leukocyte counts, total serum protein concentrations, and thrombocyte counts when compared to survivors. All nonsur-
vivors (8/8) had hyperlactatemia, whereas most survivors (6/7) had values within the reference range. All survivors had
leucocyte counts within the reference range, unlike the nonsurvivors, which showed leukopenia. During the course of acute
babesiosis, the variables serum lactate, triglyceride, and phosphate concentrations, and thrombocyte count only exceeded a
prognostic threshold during acute crisis.
Conclusions and clinical importance: Poor outcome in acute B. canis infection is indicated by changes in the laboratory
proﬁle. Intensive care should be considered for dogs presenting with moderate anemia, severe thrombocytopenia, mild to
moderate leukopenia, hyperlactatemia, moderately increased serum phosphate, and triglyceride concentrations, and moder-
ately decreased total serum protein concentrations.
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Canine babesiosis is a tick-borne disease caused byapicomplexan hemoprotozoan parasites. The 3 dis-
tinct large Babesia species, B. canis, B. vogeli, and B.
rossi, and the small B. gibsoni, B. conradae, and B.
annae have been characterized in dogs.1–3 Babesia canis
is the predominant and clinically relevant canine Babe-
sia species in Europe4 and infection typically is charac-
terized by lethargy, apathy, and pale mucous
membranes. The disorder can manifest as a mild or sev-
ere form. The clinical signs of the severe form are vari-
able and often related to an excessive inﬂammatory
response syndrome associated with multiple organ dys-
function, shock, and high mortality.3,5
Hematologic abnormalities in natural and experimen-
tal B. canis infections include anemia, thrombocytope-
nia, and inconsistent leukocyte abnormalities such as
leukocytosis, leukopenia, neutrophilia, neutropenia, and
eosinophilia. The most common abnormalities in the
serum biochemical proﬁle are increases in the activity of
aspartate aminotransferase (AST) and alanine amino-
transferase (ALT), hyperbilirubinemia, hypoalbumine-
mia, and electrolyte and acid-base abnormalities.6–10
Babesiosis in dogs aﬀects primary and secondary blood
coagulation and can induce disseminated intravascular
coagulopathy (DIC).11,12 Furthermore, a systemic
inﬂammatory response syndrome (SIRS) has been
described in acute B. canis infection characterized by an
acute phase response.12–14
The clinical manifestations of acute babesiosis are not
always proportional to the degree of anemia, and are
not correlated with the level of parasitemia, which often
remains below 1%.1,6,15 Hence, besides mechanical ery-
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throcyte damage, other pathophysiologic mechanisms
have been proposed to contribute to hemolysis, such as
toxic hemolytic factors and immune-mediated destruc-
tion of erythrocytes.16 Furthermore, disease severity
cannot be readily explained as a consequence of hemol-
ysis alone, which often is mild to moderate in acute
infections.6 Severe complications of acute Babesia infec-
tions have been described such as hemolytic and septic
shock, acute renal failure, multiple organ dysfunction
syndrome, and other complications.17,18
The clinical outcome of a B. canis infection is inﬂu-
enced by many factors and the primary pathophysio-
logic mechanisms of babesiosis in dogs remain
unclear.19,20 In canine B. rossi infections, poor progno-
sis and mortality are associated with hyperlactatemia,
hypoglycemia, clinically compromised circulation, high
parasite load, increased serum cortisol concentrations,
and signs of consumptive coagulopathy.21–25 Accord-
ingly in B. canis infections, an excessive inﬂammatory
response with increased concentrations of ﬁbrinogen, C-
reactive protein (CRP) and secreted intracellular adhe-
sion molecule-1 (sICAM-1) from erythrocytes, and
thrombocytopenia have been associated with poor out-
come.19 Furthermore, an increase in lipid mediators has
been shown to be associated with severe complications
such as development of SIRS and multiple organ dys-
function.5,26
We aimed to evaluate routine laboratory and rapid
in-clinic laboratory tests for their applicability as prog-
nostic markers associated with poor outcome in acute
B. canis infections in dogs.
Material & Methods
Animals
Naturally infected animals. The prognostic potential of diﬀerent
laboratory tests was evaluated in 15 naturally infected animals, of
which 12 dogs were presented to the Clinic for Small Animal
Internal Medicine at the Vetsuisse Faculty, University of Zurich,
and 3 dogs to private veterinary practices in Switzerland in the
years 2011 to 2013. Inclusion criteria were the presence of acute
clinical signs consistent with canine babesiosis at admission and
the identiﬁcation of large Babesia species by microscopic evalua-
tion of Giemsa-stained blood smears. In each dog, B. canis diag-
nosis was conﬁrmed by PCR27 and direct sequencing of the
amplicons.a At time of admission, blood samples were collected,
and all animals were treated with antibabesial therapy (a single
dose of 3–6 mg/kg body weight [BW] imidocarb diproprionate IM
or combined with 10 mg/kg BW doxycycline PO q12h for at least
10 days, and a second dose of imidocarb diproprionate after
14 days). Dogs were enrolled whenever inclusion criteria were met
and adequate samples were available. The animals were catego-
rized into 2 groups according to clinical outcome, which was
deﬁned as survival (survivor, n = 7 dogs) or death (nonsurvivor,
n = 8 dogs). Six of the nonsurvivors died spontaneously within
24 hours of admission and 2 dogs had to be euthanized within 48
hours because of clinical deterioration within 48 hours. Survivors
were considered to be cured based on the absence of parasites
14 days after ﬁrst admission on evaluation of Giemsa-stained
blood smears and PCR.
Experimentally-infected animals. The course of laboratory test
results was evaluated in experimentally-infected animals. Three
facility-housed adult beagles (of which 1 was 4 years and 2 were
6 years old) were inoculated IV with approximately 1 9 106 para-
sitized erythrocytes from an isolate stored in liquid nitrogen. The
parasite isolate originated from a naturally infected Bernese moun-
tain dog from Switzerland that had travelled to Hungary. The
experiments were terminated at the very ﬁrst signs of acute crisis
(which was deﬁned as weak pulse, shallow breathing, somnolence,
and any clinical signs of acute shock or central nervous depres-
sion). Experiments with dogs were conducted according to Swiss
animal rights and regulations standards and approved by the Can-
tonal Veterinary Oﬃce of Zurich (permission number 122/2012)
before the study.
Samples
Venous blood samples from the naturally infected dogs were
collected into tubes with and without ethylenediaminetetraacetic
acid (EDTA) at the time of ﬁrst admission and before any treat-
ment. Serum and EDTA-preserved blood samples were collected
through an indwelling catheter from the experimentally inoculated
dogs at diﬀerent times. In addition, citrated plasma samples were
collected from these dogs at the end of the experiments.
Analysis of blood samples
Parasitemia was expressed as the percentage of infected erythro-
cytes in Giemsa-stained blood smears by manually scanning at least
5000 erythrocytes. Exposure to Ehrlichia canis and Anaplasma
phagocytophilum was tested by an immuno-ﬂuorescence antibody
test (IFAT).b,c Complete blood cell counts were performed using
EDTA-anticoagulated blood in an automated analyzer.d Hemato-
logic analysis included total white blood cell (WBC), thrombocyte
and red blood cell (RBC) counts and RBC indices. Serum biochem-
ical proﬁles were performed using an automated analyzer.e Labora-
tory reference intervals are stated as 5% and 95% quantiles.
Portable hand-held devices for rapid in-clinic testing were used to
measure concentrations of lactatef and glucoseg immediately in
freshly collected EDTA samples.28,29 Serum CRP concentration
was determined using a canine-speciﬁc immunoturbidimetric assayh
and serum amyloid A (SAA) concentration was measured using a
latex agglutination turbimetric immunoassay on an automated ana-
lyzer.e,i In the citrated samples from the experimentally infected
animals, ﬁbrinogen concentrations were measured using the Clauss
method and a semi-automated coagulometer.j D-dimer concentra-
tions were measured on an automated analyzer.e,k
Statistical analysis
Results of the 2 groups (survivor and nonsurvivor) of natu-
rally infected dogs were compared by the Mann–Whitney U test.
The initially signiﬁcant variables then were analyzed with receiver
operator characteristic (ROC) curves for which the area under
the curve (AUC) was calculated. The ROC analysis was used for
determining a prognostic cut-oﬀ value for best diﬀerentiating
between survivors and nonsurvivors with a maximal Youden’s
index.30,31 If the cut-oﬀ value fell within the normal reference
range, it was set at the corresponding border of the reference.
Statistical analyses were performed using a statistical software
package.l A P-value < .05 was considered statistically signiﬁcant.
The hematologic and serum biochemical proﬁles from the sam-
ples collected at private practices were excluded from the analysis
because these variables were measured with other analytical
instruments. Hence, for these variables 6 survivors and 6 nonsur-
vivors were included. For parasitemia, variables from hand-held
devices, and the acute phase response, all of the naturally
infected dogs were included in the analysis (7 survivors and 8
nonsurvivors). Graphs were generated using Graph Pad.m
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Results
At admission, all of the naturally infected dogs had
diverse clinical signs consistent with canine babesiosis,
including lethargy (all 15 dogs), pale mucous membranes
(all 15 dogs), pigmenturia (10 of 15), icterus (6 of 15),
pyrexia (5 of 15), anorexia (4 of 15), vomiting (4 of 15),
“water hammer” pulse (4 of 15), and epistaxis (3 of 15).
Although Babesia infection was assumed and antibabe-
sial treatment initiated shortly after admission, 8 of the
15 dogs died or had to be euthanized within 2 days of
admission. All of the dogs were positive for B. canis in
Giemsa-stained blood smears and by PCR, and none of
these dogs reacted serologically to E. canis or A. phago-
cytophilum on IFAT. Data on characteristics of the indi-
vidual dogs (animal description, travel history, and
clinical signs) are summarized in supplemental ﬁle 1. No
statistical diﬀerence in age, sex, and clinical signs was
identiﬁed between survivors and nonsurvivors.
The parasitemia ranged between 0.5 and 3.1% (me-
dian, 1.2%; interquartile range [IQR], 0.83–1.63), but
no statistical diﬀerence was identiﬁed in the level of par-
asitemia between the survivors and nonsurvivors.
Results of laboratory ﬁndings as well as comparison
between outcome groups are summarized in Table 1. In
both groups of dogs, mild to moderate normochromic
normocytic nonregenerative anemia, mild to severe
hyperbilirubinemia, mild to moderate azotemia, mild to
moderate hypoalbuminemia, mildly increased alkaline
phosphatase (AP) activity, moderate to severe hypona-
tremia, moderate hypocalcaemia, and a mild to moder-
ate increase in CRP concentration were observed
commonly. Nonsurvivors had signiﬁcantly higher con-
centrations of lactate (P < .001), triglycerides (P < .01),
and phosphate (P < .05), and signiﬁcantly lower hemat-
ocrit (P < .05), WBC counts (P < .01), total serum pro-
tein concentrations (P < .05), and thrombocyte counts
(P < .05) than survivors.
These 7 initially identiﬁed prognostic factors were
further analyzed by ROC analysis (Table 2). Of all vari-
ables studied, lactate concentrations and WBC counts
showed the best prognostic sensitivity and speciﬁcity
(both 100%) to diﬀerentiate between survivors and non-
survivors. Fig 1 illustrates the signiﬁcant prognostic
variables for dogs in the 2 outcome groups. All nonsur-
vivors (8 of 8) had moderate to severe hyperlactatemia
(median, 8.35 mmol/L; IQR, 7.18–9.13), whereas most
survivors (6 of 7) had concentrations within the refer-
ence range (median, 1.6 mmol/L; IQR, 1.05–2.3). The
WBC counts for all of the survivors (6 of 6) were within
Table 1. Median values of various variables (minimum–maximum value) in dogs with naturally acute Babesia canis
infections: a comparison between survivors and nonsurvivors.
Variable (unit) Reference range Survivors Nonsurvivors P-value
Parasitemia (%) 1.2 (0.5–3.1) 1.25 (0.5–1.9) 1
Fast in-clinic variables
Lactate (mmol/L) <2.5 1.6 (0.5–3.6) 8.35 (4.3–11.8) <0.001
Glucose (mmol/L) 3.9–6.7 4.8 (4.3–7.6) 5.2 (3–11.9) 1
Hematologic variables
Hematocrit (%) 42–55 30 (25–40) 25.5 (17–28) 0.041
Hemoglobin (g/dL) 14.4–19.1 11.45 (9.2–14.2) 9.05 (7–18.2) 0.240
RBC (9106/lL) 6.1–8.1 4.52 (3.95–6.2) 3.95 (3.05–5.39) 0.240
MCH (pg) 23–26 24.5 (22–29) 23 (22–24) 0.180
MCHC (g/dL) 34–36 35.5 (34–36) 35 (35–39) 0.937
MCV (fL) 64–73 67.5 (64–74) 65 (58–67) 0.093
WBC (9103/lL) 4.7–11.3 6.85 (5.1–9.2) 2.65 (1.59–4.5) 0.002
Thrombocytes (9103/lL) 130–394 45 (17–190) 14.5 (6–41) 0.026
Reticulocytes (%) 0.31 (0–0.81) 0.53 (0.29–1.17) 0.132
Biochemical variables
Total bilirubin (lmol/L) <3.5 21.25 (4.7–85.3) 54.7 (19.7–221.8) 0.240
Urea (mmol/L) 3.8–9.4 12.65 (4.5–25.7) 30.45 (6.2–79.4) 0.065
Creatinine (lmol/L) 50–119 88 (75–133) 84 (54–651) 1
Total protein (g/L) 56–71 57 (40–64) 44 (34–50) 0.026
Albumin (g/L) 29–37 26.5 (19–38) 24 (13–26) 0.240
Cholesterol (mmol/L) 3.5–8.6 6.25 (4.9–7.7) 6.05 (2.7–9.3) 0.589
Triglycerides (mmol/L) 0.4–1.5 0.85 (0.8–1.1) 1.95 (0.9–3.5) 0.009
Alkaline phosphatase (U/L) 20–98 113.5 (74–184) 253.5 (61–358) 0.132
ALT (U/L) 20–93 47.5 (26–72) 72.5 (30–96) 0.132
Sodium (mmol/L) 152–159 144.5 (132–154) 142.5 (140–151) 0.485
Potassium (mmol/L) 4.3–5.3 4.2 (3.6–4.5) 4.4 (3.6–5) 0.394
Chloride (mmol/L) 113–124 113.5 (97–115) 109 (94–121) 0.485
Calcium (mmol/L) 2.4–2.8 2.43 (2.11–2.52) 2.225 (2.1–2.55) 0.180
Phosphate (mmol/L) 1.0–1.6 1.36 (1.05–1.68) 2.54 (1.39–3.08) 0.015
Acute phase response
Canine CRP (mg/L) <5 84.7 (3.3–169.8) 155.55 (22.5–232.8) 0.189
SAA (mg/L) <2.19 0 (0–2.5) 0 (0–1.1) 0.536
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the reference range (median, 6.85 9 103/lL; IQR, 6.03–
8.2) unlike the group of nonsurvivors, which had mild
to moderate leukopenia (6 of 6; median, 2.65 9 103/lL;
IQR, 1.7–3.53).
The course of the prognostic variable, parasitemia,
and the acute phase response was followed in the 3
dogs experimentally inoculated with B. canis. The 3
infected dogs became lethargic and showed signs of
hemolysis (pale mucous membranes and pigmenturia)
105, 120, and 119 hours postinoculation (on days 4–5),
respectively. They had a low grade parasitemia with a
maximum of 1.75% of the erythrocytes infected at the
end of the experiment, and during the course 2 of the
3 dogs had episodes of pyrexia (Fig 2A). An acute
phase response could be observed with a moderate
increase in CRP concentration and a moderate decrease
in serum albumin concentration (Fig 2B), whereas
SAA concentrations remained below the diagnostic
Table 2. Results of the ROC analysis with prognostic cut-oﬀ values of signiﬁcantly altered variables and respective
sensitivity, speciﬁcity, area under the curve (AUC), and standard error (SE) associated with the outcome in Babesia
canis infected dogs.
Parameter (unit) Prognostic cut-oﬀ value Sensitivity (%) Speciﬁcity (%) AUC SE
Lactate (mmol/L) 3.95 100 100 1.00 0.00
Hematocrit (%) 28.5 66.7 100 0.86 0.11
WBC (9103/lL) 4.7a 100 100 1.00 0.00
Thrombocytes (9103/lL) 27.5 83.3 83.3 0.89 0.10
Total protein (g/L) 50.5 83.3 100 0.88 0.12
Triglycerides (mmol/L) 1.5 83.3 100 0.94 0.07
Phosphate (mmol/L) 1.72 83.3 100 0.92 0.09
aSet at the border of the reference range (calculated cut-oﬀ at 4.8 9 103/lL).
Fig 1. Prognostic markers in acute Babesia canis infected dogs. Median and interquartile range for signiﬁcant prognostic markers
(P < .05) recorded at admission in naturally infected dogs that did or did not survive an acute B. canis infection. Dots correspond to the
data from individual dogs; the shaded grey areas represent the reference intervals. WBC: white blood cells.
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limit (data not shown). Follow-up of prognostic mark-
ers is shown in Fig 3. A decrease in the hematologic
variables leukocytes, thrombocytes, and hematocrit was
found before the identiﬁcation of parasites in stained
blood smears, and resulted in moderate leukopenia,
severe thrombocytopenia, and decreased hematocrit. In
general, mild to moderate anemia was observed.
Changes in lactate, triglyceride, and phosphate concen-
trations corresponded to the ﬁrst appearance of para-
sites, and they only exceeded the prognostic threshold
at the ﬁrst observation of acute crisis. In addition,
thrombocytopenia was a common ﬁnding and platelet
counts exceeded the prognostic threshold toward the
end of the experiment. Total serum protein concentra-
tions also decreased over time but passed the thresh-
old only in 2 of the 3 dogs before ﬁrst signs of
an acute breakdown. At the end of the experiment, the
3 dogs showed mildly increased levels of ﬁbrinogen
of 2.6 g/L, 3.8 g/L, and 3.2 g/L (reference range,
1.0–2.5 g/L), and D-dimer concentrations of 0.26 mg/
L, 0.44 mg/L, and 0.92 mg/L (reference range,
<0.4 mg/L), respectively.
Discussion
In this study, several variables were shown to be
associated with poor outcome in acute Babesia canis
infections. By including 2 rapid in-clinic tests, standard
hematologi and biochemical variables, and acute phase
proteins, we found the variables lactate, WBC, triglyc-
erides, phosphate, thrombocytes, total serum protein,
and hematocrit to be signiﬁcant prognostic markers.
Thus, nonsurvivors at admission had more severe ane-
mia, leukopenia, and thrombocytopenia in addition to
alterations in their serum biochemical proﬁle results.
Lactate concentrations were signiﬁcantly lower in sur-
vivors and showed a clear diﬀerence from the nonsur-
vivors. This ﬁnding is similar to what is observed in
dogs infected with Babesia rossi, the agent of severe
canine babesiosis in South Africa, where serum lactate
concentration is used for post-treatment monitoring,21
and high blood lactate concentrations correlate with
poor outcome.32–34 Nevertheless, the pathogenesis of
hyperlactatemia in dogs with acute babesiosis is not
well established, and it might not be caused by hypoxia
as a consequence of anemia, which remains mild to
moderate in most B. canis infected animals.34 Hence,
hypoxia in canine babesiosis may be the consequence of
alterations in the macro- and micro-cirulation triggered
by protozoal sepsis, hypotension, DIC, and SIRS, all of
which are well known in B. canis infections18,35. Indeed,
increased lactate concentrations have prognostic value
in SIRS caused by various conditions.36,37
The second variable that clearly diﬀerentiates between
the 2 studied groups was WBC count. Nonsurvivors had
mild to moderate leukopenia in contrast to the survivors
with WBC counts in the reference range. Although the
WBC count was a signiﬁcant marker for outcome in our
study, leukopenia was reported in 60% of mild cases of
acute canine babesiosis.17 Indeed, the WBC count fell
below the prognostic cut-oﬀ before any clinical signs
were observed in the experimentally inoculated dogs.
Severely aﬀected dogs had mild to moderate neutrope-
nia, with an overall degenerative tendency and lacking a
left shift (see supplemental ﬁle 2). Furthermore, lym-
phopenia seems to be a hallmark of acute canine
babesiosis.17,19 A markedly increased serum cortisol con-
centration was found in dogs with lethal B. rossi infec-
tions, indicating a potential immunosuppressed state in
these animals, which also is indicated by an unexpected
mild to moderate regenerative response of lymphocytes
in dogs that survived.24,38 Furthermore, studies in
humans with acute malaria infections with Plasmodium
falciparum and P. vivax, which are related to Babesia
spp., identiﬁed mechanisms that could explain a deple-
tion of lymphocytes from the peripheral blood by acute
sequestration of the cells in the lymph nodes or other
parts of the body or by immune cell exhaustion and
abnormal cell death through parasite-induced apopto-
sis.39,40 Similarly, toxic parasitic factors have been
shown to be involved in canine B. gibsoni infection.41
Hemolytic anemia and thrombocytopenia are the
most frequent abnormalities associated with a diagnosis
of B. canis in naturally infected dogs and thrombocy-
Fig 2. Course of selected variables in 3 experimentally infected
dogs. Dog 1: solid line; dog 2: broken line; dog 3: dotted line. (A)
Body temperature (left y-axis) and parasitemia (right y-axis; lines
with dots). The shaded grey area represents the reference interval
for the body temperature. (B) CRP (left y-axis) as a marker for
positive acute phase response and albumin (right y-axis; lines with
dots) as a marker for negative acute phase response. The shaded
grey area represents the reference interval for albumin. hpi: hours
postinfection, CRP: C-reactive protein.
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topenia usually is the most dramatic hematologic
abnormality in the course of babesiosis.12,42–44 Our data
indicate that severe thrombocytopenia is associated with
poor outcome by a prognostic cut-oﬀ of 27,500 throm-
bocytes per lL, although a sensitivity and speciﬁcity of
83.3% for each indicates limited prognostic value. Pre-
sumably, several factors are involved in the origin of
thrombocytopenia in canine babesiosis including
increased platelet activation and consumption by a
SIRS (hypercoagulable state), increased platelet seques-
tration and aggregation, and a decreased platelet pro-
duction.19,45,46 Comparable in B. rossi infections, poor
outcome was associated with a consumptive coagulopa-
thy, although even severe thrombocytopenia was not
accompanied by apparent bleeding diathesis and hemor-
rhage.25,47,48
Increased phosphate concentrations often are associ-
ated with metabolic acidosis characterized by tissue
hypoxia and high blood lactate concentrations,
although the underlying mechanisms have not been
completely explained.49 Hemorrhage, hypovolemia, and
shock as cause or consequence of tissue hypoperfusion
A B
C D
E F
G
Fig 3. Course of signiﬁcant prognostic markers in 3 experimentally-infected dogs. Dog 1: solid line; dog 2: broken line; dog 3: dotted line.
The shaded grey areas represent the reference intervals. The horizontal broken lines represent the corresponding prognostic cut-oﬀ.
(A) blood lactate, (B) WBC, (C) triglycerides, (D) phosphate, (E) thrombocyte count, (F) total protein, (G) hematocrit. hpi: hours postin-
fection, WBC: white blood cells.
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could further explain changes in altered variables, also
including azotemia and potential protein-losing
nephropathy caused by hypoxic renal damage.35 Com-
plications related to hemolytic anemia, coagulation dis-
orders and hypotension, SIRS, and secondary impaired
renal function likely account for the severe outcome of
the infection.6,9,10,12 Furthermore, in other studies, acute
respiratory distress syndrome, renal failure, immune-
mediated hemolytic anemia, cerebral syndrome, and
DIC were associated with increased mortality in acute
B. canis infections.17,50
Acute phase proteins were used as prognostic factors
for diﬀerent inﬂammatory processes,51 and an acute
phase response also was observed in acute B. canis
infections.12–14,20 We measured the acute phase proteins
CRP and SAA, because they are considered major APP
in dogs52 and are not signiﬁcantly aﬀected by hyper-
bilirubinemia, which is commonly present in acute
babesiosis.51 We found an increase in CRP before para-
site detection as previously observed,12 without any sig-
niﬁcant diﬀerence between the outcome groups. This
ﬁnding is in accordance with ﬁndings in B. rossi infec-
tions in which no prognostic value for CRP concentra-
tions was observed.53 Furthermore, the SAA
concentrations did not increase signiﬁcantly in naturally
and experimentally infected animals. This ﬁnding is in
contrast to other observations of increased SAA con-
centrations in dogs with babesiosis on the day of admis-
sion.14 As another indicator, serum albumin
concentration could serve as a negative APP.51 With
the onset of acute infection, we observed a moderate
decrease in serum albumin concentration and it had no
prognostic relevance. Although diﬀerences between sur-
vivors and nonsurvivors were absent for an acute phase
response, APP (among other variables) could serve as
important variables for monitoring response to ther-
apy.14,54
In the course of validating prognostic markers in 3
experimentally inoculated dogs, we observed low grade
parasitemia with a maximum of 1.75% of infected
erythrocytes, which was comparable to the group of
naturally infected animals. Even in infections with
serious clinical signs, low parasitemia is a common
ﬁnding in B. canis infections.1,6,12 The course in the
infected dogs highlights the prognostic value of lac-
tate, triglycerides, and phosphate concentrations, and
thrombocyte counts, because these factors only
crossed the prognostic threshold in an acute crisis.
Referring to the ROC analysis of these variables, only
lactate showed optimal characteristics. Therefore, any
prognosis based on individual variables should be
interpreted with caution.
Missing data about the course of disease before
admission and the time point of infection in the natu-
rally infected dogs is a limitation of this study. Gen-
erally, practitioners inquire about the duration of
illness and the appearance of the ﬁrst clinical signs,
and they can estimate the time of the infection in
aﬀected dogs. In this respect, the prognostic markers
are helpful for guiding clinical decision making. To
get an overall picture of individual cases, a systematic
collection of clinical, laboratorial, and other individual
factors must be emphasized. For example, in our
cohort of infected dogs, circulatory disturbances were
detected in 4 relatively young dogs (7 month to
approximately 3 years), of which 3 dogs died (see
supplemental ﬁle 1). Such clinical variables could
aﬀect outcome in the laboratory test results and the
likely progression of a patient’s infection.55 In any
case, outcome depends on a rapid diagnosis and early
treatment.
Mortality in the investigated group of dogs was
higher as compared to an endemic area.5 This ﬁnding
reﬂects a typical situation for nonendemic areas such as
Switzerland, where dogs became infected from local
Babesia outbreaks or have traveled to an endemic area.
These dogs likely never have had contact with the
parasite and therefore did not develop partial immu-
nity.46,56 Nonetheless, ﬁndings on mortality rates
should not be over interpreted because of the small
sample size. In our cohort, we included every possible
case for which we could obtain comparable clinico-
pathologic data.
Unfortunately, we did not have precise data about
infection rates in dogs in Switzerland. However, during
the sampling period, 2 indigenous outbreaks were
reported in 44 dogs, of which 10 died.57,58 Most
indigenous cases in our cohort originated from these
areas (4 survivors and 1 nonsurvivor), whereas 1 dog
originated from Geneva, a known endemic region in
Switzerland.59 The remaining 9 infected dogs had a
positive travel history. Information about infection
rate in dogs in Switzerland that have travelled is rare.
For example, from 2011 to 2013, the diagnostic unit
of the Institute of Parasitology in Zurich (which oﬀers
a travel screening panel) identiﬁed 2.1% of 804
samples as positive on blood smears for large Babesia
species (F. Grimm, personal communication). This
observation is in agreement with observed cases in
dogs in Germany that have travelled, with 3.7% (19/
508) of animals positive for large Babesia spp. in
Giemsa-stained blood or buﬀy coat smears.60 Hence,
to compensate for the small sample size, prognostic
markers were cross-validated in the course of experi-
mental babesiosis.
Although a signiﬁcant prognostic marker is not nec-
essarily clinically relevant, the pathophysiologic reason
for death would be of interest. With this in mind, addi-
tional studies should include postmortem examination,
and more prognostic factor studies should be conducted
including other nonroutine variables. This study focused
on rapid in-practice tests (e.g. lactate and glucose deter-
mined by hand-held analyzers) and routine laboratory
variables, and the associated ﬁndings summarize the
prognostic value of these variables. Nevertheless, addi-
tional research is needed to evaluate what additional
evaluation and intensive care is needed for dogs with a
poor prognosis. In this context, several markers have
been demonstrated as good variables for follow-up and
post-treatment monitoring after antibabesial therapy,
such as APP, lactate, thrombocytes, and leuko-
cytes.13,14,21,43,54
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Footnotes
a Synergene GmbH, Schlieren, Switzerland
b Mega Screen Fluoehrlichia c., MegaCor Diagnostik GmbH,
H€orbranz, Austria
c E. equi FA substrate slide, VMRD, Inc. Pulma, Washington,
USA
d Sysmex XT-2000iV, Sysmex Corporation, Kobe, Japan
e Cobas Integra 800, Roche Diagnostics, Rotkreuz, Switzerland
f Lactate Pro, Axon Lab AG, Baden, Switzerland
g Accu-Chek, Roche Diagnostics AG, Rotkreuz, Switzerland
h Gentian cCRP; Gentian AS, Moss, Norway
i LZ Test SAA; Eiken Chemical Co., Ltd., Tokyo, Japan
j STart 4, Roche Diagnostics AG, Rotkreuz, Switzerland
k Tina-quant D-Dimer Gen.2, Roche Diagnostics AG, Rotkreuz,
Switzerland
l IBM SPSS statistics, 20.0.0, IBM Corp. Armonk, NY, USA
mGraph Pad Prism 4, Graph Pad Software, San Diego, USA
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